TG Therapeutics (TGTX)
(Real Time Quote from BATS)
$20.11 USD
+0.12 (0.60%)
Updated Aug 8, 2024 11:58 AM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Brokerage Reports
TG Therapeutics, Inc. [TGTX]
Reports for Purchase
Showing records 21 - 40 ( 277 total )
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Briumvi Commercial Launch Announced Ahead of Schedule
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Briumvi Approved for MS Treatment; Reit. Buy; PT Raised to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
3Q22 Results; Ublituximab in RMS December 28, 2022, PDUFA Date With Potential Commercial Launch in Early 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Additional Data in ECTRIMS Abstracts Support Approval and Use of Ublituximab in Multiple Sclerosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
2Q22 Results; All Focus on the MS Opportunity for Ublituximab
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Positive ULTIMATE I and II Data Presentations at EAN
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Extension of BLA PDUFA Date for Ublituximab in Relapsing Forms of Multiple Sclerosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Data Presentations Announced from ULTIMATE I and II Trials to be Presented at CMSC Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
1Q22 Results; Waiting on Launch of Ublituximab in MS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
With OS Data Favoring the Control Arm, Ukoniq BLA/ sNDA Withdrawn and Pulled From Marketed Indications
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Following the Withdrawal of Ukoniq, All Eyes on Ublituximab in MS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ODAC Meeting Scheduled Within Expected Timeframe
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Planned ULTIMATE I & II Data Presentations Announced for AAN Annual Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Extension of PDUFA Goal Date for U2 in CLL/SLL BLA/sNDA to June 25, 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
ULTIMATE I and II Trials Presentations at ACTRIMS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Three ACTRIMS Meeting Abstracts for ULTIMATE I and II Trials Released
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: TG Therapeutics, Inc.
Industry: Medical - Products
Partial Clinical Hold Announced for U2; Lower PT by $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E